Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.03
TECH's Cash to Debt is ranked lower than
79% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. TECH: 1.03 )
Ranked among companies with meaningful Cash to Debt only.
TECH' s 10-Year Cash to Debt Range
Min: 0.89  Med: 10000.00 Max: No Debt
Current: 1.03
Equity to Asset 0.74
TECH's Equity to Asset is ranked higher than
56% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TECH: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
TECH' s 10-Year Equity to Asset Range
Min: 0.69  Med: 0.91 Max: 0.98
Current: 0.74
0.69
0.98
F-Score: 4
Z-Score: 10.60
M-Score: -3.93
WACC vs ROIC
2.28%
14.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 34.67
TECH's Operating margin (%) is ranked higher than
93% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. TECH: 34.67 )
Ranked among companies with meaningful Operating margin (%) only.
TECH' s 10-Year Operating margin (%) Range
Min: 22.34  Med: 51.02 Max: 58.1
Current: 34.67
22.34
58.1
Net-margin (%) 25.34
TECH's Net-margin (%) is ranked higher than
90% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. TECH: 25.34 )
Ranked among companies with meaningful Net-margin (%) only.
TECH' s 10-Year Net-margin (%) Range
Min: 15.75  Med: 32.82 Max: 40.8
Current: 25.34
15.75
40.8
ROE (%) 13.51
TECH's ROE (%) is ranked higher than
87% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. TECH: 13.51 )
Ranked among companies with meaningful ROE (%) only.
TECH' s 10-Year ROE (%) Range
Min: 14.12  Med: 21.62 Max: 27.17
Current: 13.51
14.12
27.17
ROA (%) 10.97
TECH's ROA (%) is ranked higher than
90% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. TECH: 10.97 )
Ranked among companies with meaningful ROA (%) only.
TECH' s 10-Year ROA (%) Range
Min: 11.96  Med: 18.93 Max: 23.99
Current: 10.97
11.96
23.99
ROC (Joel Greenblatt) (%) 68.90
TECH's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. TECH: 68.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TECH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 52.09  Med: 94.86 Max: 120.19
Current: 68.9
52.09
120.19
Revenue Growth (3Y)(%) 7.40
TECH's Revenue Growth (3Y)(%) is ranked higher than
59% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. TECH: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TECH' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.4  Med: 12.15 Max: 16.4
Current: 7.4
5.4
16.4
EBITDA Growth (3Y)(%) 1.60
TECH's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. TECH: 1.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TECH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 1.6  Med: 13.40 Max: 41.3
Current: 1.6
1.6
41.3
EPS Growth (3Y)(%) -0.20
TECH's EPS Growth (3Y)(%) is ranked higher than
58% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. TECH: -0.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TECH' s 10-Year EPS Growth (3Y)(%) Range
Min: -0.2  Med: 17.35 Max: 36.3
Current: -0.2
-0.2
36.3
» TECH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TECH Guru Trades in Q2 2014

Paul Tudor Jones 5,500 sh (+61.76%)
Columbia Wanger 1,212,200 sh (+58.73%)
Bill Frels 1,095,391 sh (+10.00%)
Jeremy Grantham 48,243 sh (+4.32%)
Ron Baron 1,053,380 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Chuck Royce 641,750 sh (-1.57%)
Jim Simons 510,100 sh (-11.70%)
» More
Q3 2014

TECH Guru Trades in Q3 2014

Ray Dalio 2,300 sh (New)
Paul Tudor Jones 7,200 sh (+30.91%)
Columbia Wanger 1,332,700 sh (+9.94%)
Ron Baron 1,053,380 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Bill Frels 1,090,022 sh (-0.49%)
Jim Simons 494,500 sh (-3.06%)
Chuck Royce 620,205 sh (-3.36%)
Jeremy Grantham 39,041 sh (-19.07%)
» More
Q4 2014

TECH Guru Trades in Q4 2014

Ray Dalio 3,982 sh (+73.13%)
Bill Frels 1,295,420 sh (+18.84%)
Columbia Wanger 1,483,300 sh (+11.30%)
Jim Simons 526,700 sh (+6.51%)
Ruane Cunniff 2,540 sh (unchged)
Ron Baron 1,053,220 sh (-0.02%)
Chuck Royce 611,825 sh (-1.35%)
Paul Tudor Jones 5,600 sh (-22.22%)
Jeremy Grantham 28,400 sh (-27.26%)
» More
Q1 2015

TECH Guru Trades in Q1 2015

Ray Dalio 4,282 sh (+7.53%)
Bill Frels 1,379,687 sh (+6.50%)
Ruane Cunniff 2,540 sh (unchged)
Ron Baron 1,053,220 sh (unchged)
Columbia Wanger 1,483,300 sh (unchged)
Jeremy Grantham 27,100 sh (-4.58%)
Paul Tudor Jones 4,100 sh (-26.79%)
Chuck Royce 401,385 sh (-34.40%)
Jim Simons 281,100 sh (-46.63%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 37.70
TECH's P/E(ttm) is ranked higher than
54% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. TECH: 37.70 )
Ranked among companies with meaningful P/E(ttm) only.
TECH' s 10-Year P/E(ttm) Range
Min: 16.76  Med: 26.57 Max: 37.67
Current: 37.7
16.76
37.67
Forward P/E 27.32
TECH's Forward P/E is ranked lower than
58% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. TECH: 27.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 37.70
TECH's PE(NRI) is ranked higher than
53% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. TECH: 37.70 )
Ranked among companies with meaningful PE(NRI) only.
TECH' s 10-Year PE(NRI) Range
Min: 16.78  Med: 26.62 Max: 37.72
Current: 37.7
16.78
37.72
P/B 4.96
TECH's P/B is ranked lower than
52% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TECH: 4.96 )
Ranked among companies with meaningful P/B only.
TECH' s 10-Year P/B Range
Min: 3.27  Med: 4.84 Max: 8.27
Current: 4.96
3.27
8.27
P/S 9.52
TECH's P/S is ranked higher than
56% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. TECH: 9.52 )
Ranked among companies with meaningful P/S only.
TECH' s 10-Year P/S Range
Min: 6.73  Med: 9.34 Max: 12.59
Current: 9.52
6.73
12.59
PFCF 32.46
TECH's PFCF is ranked higher than
64% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. TECH: 32.46 )
Ranked among companies with meaningful PFCF only.
TECH' s 10-Year PFCF Range
Min: 17.73  Med: 25.59 Max: 37.34
Current: 32.46
17.73
37.34
POCF 29.01
TECH's POCF is ranked higher than
59% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. TECH: 29.01 )
Ranked among companies with meaningful POCF only.
TECH' s 10-Year POCF Range
Min: 15.71  Med: 23.36 Max: 31.39
Current: 29.01
15.71
31.39
EV-to-EBIT 27.73
TECH's EV-to-EBIT is ranked higher than
56% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. TECH: 27.73 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s 10-Year EV-to-EBIT Range
Min: 10.4  Med: 17.10 Max: 27.5
Current: 27.73
10.4
27.5
PEG 13.96
TECH's PEG is ranked lower than
84% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. TECH: 13.96 )
Ranked among companies with meaningful PEG only.
TECH' s 10-Year PEG Range
Min: 1.01  Med: 2.06 Max: 21.19
Current: 13.96
1.01
21.19
Shiller P/E 34.87
TECH's Shiller P/E is ranked higher than
67% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. TECH: 34.87 )
Ranked among companies with meaningful Shiller P/E only.
TECH' s 10-Year Shiller P/E Range
Min: 21.02  Med: 29.96 Max: 51.1
Current: 34.87
21.02
51.1
Current Ratio 7.65
TECH's Current Ratio is ranked higher than
65% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. TECH: 7.65 )
Ranked among companies with meaningful Current Ratio only.
TECH' s 10-Year Current Ratio Range
Min: 3.27  Med: 9.69 Max: 21.99
Current: 7.65
3.27
21.99
Quick Ratio 6.33
TECH's Quick Ratio is ranked higher than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. TECH: 6.33 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s 10-Year Quick Ratio Range
Min: 2.82  Med: 9.02 Max: 21.04
Current: 6.33
2.82
21.04
Days Inventory 125.85
TECH's Days Inventory is ranked lower than
53% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. TECH: 125.85 )
Ranked among companies with meaningful Days Inventory only.
TECH' s 10-Year Days Inventory Range
Min: 63.05  Med: 73.78 Max: 192.76
Current: 125.85
63.05
192.76
Days Sales Outstanding 56.30
TECH's Days Sales Outstanding is ranked higher than
54% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. TECH: 56.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s 10-Year Days Sales Outstanding Range
Min: 40.81  Med: 46.28 Max: 66.4
Current: 56.3
40.81
66.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.16
TECH's Dividend Yield is ranked higher than
55% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. TECH: 1.16 )
Ranked among companies with meaningful Dividend Yield only.
TECH' s 10-Year Dividend Yield Range
Min: 0.39  Med: 1.50 Max: 1.82
Current: 1.16
0.39
1.82
Dividend Payout 0.43
TECH's Dividend Payout is ranked lower than
63% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. TECH: 0.43 )
Ranked among companies with meaningful Dividend Payout only.
TECH' s 10-Year Dividend Payout Range
Min: 0.3  Med: 0.38 Max: 0.49
Current: 0.43
0.3
0.49
Dividend growth (3y) 4.80
TECH's Dividend growth (3y) is ranked lower than
56% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. TECH: 4.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
TECH' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 14
Current: 4.8
0
14
Yield on cost (5-Year) 1.76
TECH's Yield on cost (5-Year) is ranked higher than
62% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.32 vs. TECH: 1.76 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TECH' s 10-Year Yield on cost (5-Year) Range
Min: 0.59  Med: 2.28 Max: 2.76
Current: 1.76
0.59
2.76
Share Buyback Rate 0.10
TECH's Share Buyback Rate is ranked higher than
92% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. TECH: 0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
TECH' s 10-Year Share Buyback Rate Range
Min: 2  Med: 0.80 Max: -2.9
Current: 0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 390.64
TECH's Price/Net Current Asset Value is ranked lower than
99% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. TECH: 390.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TECH' s 10-Year Price/Net Current Asset Value Range
Min: 6.89  Med: 11.88 Max: 358.18
Current: 390.64
6.89
358.18
Price/Tangible Book 29.64
TECH's Price/Tangible Book is ranked lower than
92% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. TECH: 29.64 )
Ranked among companies with meaningful Price/Tangible Book only.
TECH' s 10-Year Price/Tangible Book Range
Min: 4.14  Med: 6.11 Max: 32.42
Current: 29.64
4.14
32.42
Price/Projected FCF 2.07
TECH's Price/Projected FCF is ranked higher than
78% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. TECH: 2.07 )
Ranked among companies with meaningful Price/Projected FCF only.
TECH' s 10-Year Price/Projected FCF Range
Min: 1.27  Med: 2.04 Max: 12.77
Current: 2.07
1.27
12.77
Price/DCF (Earnings Based) 2.80
TECH's Price/DCF (Earnings Based) is ranked lower than
71% of the 14 Companies
in the Global Biotechnology industry.

( Industry Median: 1.36 vs. TECH: 2.80 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.01
TECH's Price/Median PS Value is ranked higher than
61% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. TECH: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
TECH' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 0.98 Max: 2.79
Current: 1.01
0.36
2.79
Price/Graham Number 7.03
TECH's Price/Graham Number is ranked lower than
75% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. TECH: 7.03 )
Ranked among companies with meaningful Price/Graham Number only.
TECH' s 10-Year Price/Graham Number Range
Min: 1.96  Med: 2.71 Max: 10.74
Current: 7.03
1.96
10.74
Earnings Yield (Greenblatt) (%) 3.60
TECH's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TECH: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TECH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.6  Med: 5.90 Max: 9.6
Current: 3.6
3.6
9.6
Forward Rate of Return (Yacktman) (%) 4.68
TECH's Forward Rate of Return (Yacktman) (%) is ranked lower than
67% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. TECH: 4.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TECH' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 4.7  Med: 15.40 Max: 26.5
Current: 4.68
4.7
26.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TE1.Germany,
Bio-Techne Corp is engaged in the development, manufacture and sale of biotechnology products and clinical diagnostic controls. Its business is segmented into two areas - Biotechnology and Hematology. The Biotechnology segment offers proteins, such as cytokines, and enzyme substrates and inhibitors; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits for the detection of human and animal proteins, and immunoassays that allow researchers to quantify a specific analyte in a biological fluids sample; clinical diagnostic immunoassay kits consisting of erythropoietin, transferrin receptor, and beta2-microglobulin immunoassays for use as in vitro diagnostic devices; flow cytometry products, such as fluorochrome labeled antibodies and kits; intracellular cell signaling products, including antibodies, phospho-specific antibodies, antibody arrays, active caspases, kinases, phosphatases, and enzyme-linked immunosorbant assays to measure the activity of apoptotic and signaling molecules; and natural and synthetic chemical compounds for use as agonists, antagonists, and inhibitors of various biological functions by investigators. The Hematology segment provides a range of hematology controls and calibrators for impedance and laser type cell counters; and hematology control products for use as proficiency testing tools by laboratory certifying authorities. The Company serves biotechnology research market and the clinical diagnostics market.
» More Articles for TECH

Headlines

Articles On GuruFocus.com
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Discounted cash flow Jul 17 2011 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 
Comment for Buffett-Munger Screener - Good Companies at Fair or Undervalued Prices Apr 23 2010 
Techne Corp. Reports Operating Results (10-Q) Feb 08 2010 

More From Other Websites
Bio-Techne (TECH) is in Overbought Territory: What's Next? - Tale of the Tape Jul 24 2015
Bio-Techne To Host Conference Call On August 6, 2015 To Announce Fourth Quarter Financial Results Jul 14 2015
4 Stocks Rising on Unusual Volume Jul 07 2015
Bio-Techne to Buy Cliniqa, Boost Clinical Controls Portfolio - Analyst Blog Jun 08 2015
BIO-TECHNE CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 08 2015
Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation Jun 05 2015
Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation Jun 05 2015
BIO-TECHNE CORP Financials May 19 2015
Bio-Techne Lags on Q3 Earnings, Revenues; Expenses Rise - Analyst Blog May 11 2015
BIO-TECHNE CORP Files SEC form 10-Q, Quarterly Report May 11 2015
Bio-Techne Declares Dividend May 05 2015
Bio-Techne Releases Third Quarter Fiscal 2015 Results May 05 2015
Techne misses Street 3Q forecasts May 05 2015
Techne misses Street 3Q forecasts May 05 2015
BIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 05 2015
Q3 2015 Bio-Techne Corp Earnings Release - Before Market Open May 05 2015
Bio-Techne Releases Third Quarter Fiscal 2015 Results May 05 2015
Bio-Techne Declares Dividend May 05 2015
Bio-Techne To Host Conference Call On May 5, 2015 To Announce Third Quarter Financial Results Apr 23 2015
Stocks Trade Near Lows; Chinese Issues Hammered Apr 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK